Anti-Atherosclerotic Effects of Vitamins D and E in Suppression of Atherogenesis

Journal of Cellular Physiology

Volumn 232, Issue 11, 2017, Pages 2968-2976

  Rashidi, Bahman ^a   Hoseini, Zahra ^a   Sahebkar, Amirhossein ^b   Mirzaei, Hamed ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; MICRORNA; OXYGEN; VITAMIN D; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE;

ALPHA TOCOPHEROL DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DRUG EFFECT; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANIMAL; ARTERY; ATHEROSCLEROSIS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARTERIES; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; MICRORNAS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; SUPEROXIDES; VITAMIN D; VITAMIN E;

EID: 85018477580     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25738     Document Type: Review

References (153)

1. Amento EP, Ehsani N, Palmer H, Libby P. 1991. Cytokines and growth factors Positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11:1223–1230.
2. Andrés V. 2014. Vitamin D puts the brakes on angiotensin II-induced oxidative stress and vascular smooth muscle cell senescence. Atherosclerosis 236:444–447.
3. Arabpour M, Mohammadparast S, Maftouh M, ShahidSales S, Moieni S, Akbarzade H, Mirhafez SR, Parizadeh SM, Hassanian SM, Avan A. 2016. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in gastric cancer: Current status and future perspectives. Curr Med Chem 2016 Aug 17. [Epub ahead of print] PubMed PMID: 27538692.
4. Azzi A, Ricciarelli R, Zingg J-M. 2002. Non-antioxidant molecular functions of α-tocopherol (vitamin E). FEBS Lett 519:8–10.
5. Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F, Mercier J-P, Têtu B, Harel F, Mâsse B. 2005. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481–488.
6. Banikazemi Z, Mokhber N, Safarian M, Mazidi M, Mirzaei H, Esmaily H, Azarpazhooh MR, Ghafouri-Taleghani F, Ghayour-Mobarhan M, Ferns GA. 2015. Dietary vitamin E and fat intake are related to Beck's depression score. Clin Nutr ESPEN 10:e61–e65.
7. Bao-Liang Z. 2009. Tetrahydrobiopterin and cardiovascular disease. Med Recap 4:012.
8. Barchowsky A, Munro SR, Morana SJ, Vincenti MP, Treadwell M. 1995. Phosphorylation-dependent activation, of NF-kappa B and AP-1 in endothelial cells. Am J Physiol 269:L829–L836.
9. Borghaei RC, Rawlings PL, Javadi M, Woloshin J. 2004. NF-κB binds to a polymorphic repressor element in the MMP-3 promoter. Biochem Biophys Res Commun 316:182–188.
10. Brasier AR. 2010. The nuclear factor-κB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86:211–218.
11. Brewer LC, Michos ED, Reis JP. 2011. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 12:54–60.
12. Briley-Saebo KC, Cho YS, Tsimikas S. 2011. Imaging of oxidation-specific epitopes in atherosclerosis and macrophage-rich vulnerable plaques. Curr Cardiovasc Imaging Rep 4:4–16.
13. Burton GW, Traber MG. 1990. Vitamin E: Antioxidant activity, biokinetics, and bioavailability. Annu Rev Nutr 10:357–382.
14. Busse R, Lackhoff A, Bassenge E. 1987. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn Schmiedebergs Arch Pharmacol 336:566–571.
15. Cachia O, Benna El, Descomps E, Gougerot-Pocidalo B, Leger M-A. 1998. α-tocopherol inhibits the respiratory burst in human monocytes attenuation of p47 phox membrane translocation and phosphorylation. J Biol Chem 273:32801–32805.
16. Cadenas E, Sies H. 1985. Oxidative stress: Excited oxygen species and enzyme activity. Adv Enzyme Regul 23:217–237.
17. Carr AC, McCall MR, Frei B. 2000. Oxidation of LDL by myeloperoxidase and reactive nitrogen species reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20:1716–1723.
18. Chen K-C, Juo S-HH. 2012. MicroRNAs in atherosclerosis. Kaohsiung J Med Sci 28:631–640.
19. Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. 2013. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. J Biol Chem 288:19450–19458.
20. Chisolm GM, Steinberg D. 2000. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 28:1815–1826.
21. Cho K-J, Seo J-M, Kim J-H. 2011. Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species. Mol Cells 32:1–5.
22. Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. 2000. Upregulation of p67 phox and gp91 phox in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 279:H2234–H2240.
23. Collins T, Cybulsky MI. 2001. NF-κB: Pivotal mediator or innocent bystander in atherogenesis? J Clinical Invest 107:255–264.
24. Collins T, Ginsburg D, Boss JM, Orkin SH, Pober JS. 1985. Cultured human endothelial cells express platelet-derived growth factor B chain: CDNA cloning and structural analysis. Nature 316:748–750.
25. Cooke JP. 2004. Asymmetrical dimethylarginine the Über marker? Circulation 109:1813–1818.
26. Davignon J, Ganz P. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109:III-27–III- 32.
27. De Donatis A, Comito G, Buricchi F, Vinci MC, Parenti A, Caselli A, Manao G, Ramponi G, Cirri P. 2008. Proliferation versus migration in platelet-derived growth factor signaling the key role of endocytosis. J Biol Chem 283:19948–19956.
28. Deanfield JE, Halcox JP, Rabelink TJ. 2007. Endothelial function and dysfunction testing and clinical relevance. Circulation 115:1285–1295.
29. Devaraj S, Jialal I. 1999. α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 19:1125–1133.
30. Devaraj S, Hugou I, Jialal I. 2001. α-Tocopherol decreases CD36 expression in human monocyte-derived macrophages. J Lipid Res 42:521–527.
31. Dröge W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82:47–95.
32. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. 1998. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci 95:8880–8885.
33. Fathullahzadeh S, Mirzaei H, Honardoost M, Sahebkar A, Salehi M. 2016. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther 23:327–332.
34. Fleming I, Busse R. 2003. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284:R1–R12.
35. Fleming I, Mohamed A, Galle J, Turchanowa L, Brandes RP, Fisslthaler B, Busse R. 2005. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCα. Cardiovasc Res 65:897–906.
36. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. 1994. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 23:1121–1131.
37. Freedman JE, Farhat JH, Loscalzo J, Keaney JF. 1996. α-Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 94:2434–2440.
38. Gao YT, Roman LJ, Martásek P, Panda SP, Ishimura Y, Masters BSS. 2007. Oxygen metabolism by endothelial nitric-oxide synthase. J Biol Chem 282:28557–28565.
39. Gharavi NM, Baker NA, Mouillesseaux KP, Yeung W, Honda HM, Hsieh X, Yeh M, Smart EJ, Berliner JA. 2006. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ Res 98:768–776.
40. Gholamin S, Pasdar A, Sadegh Khorrami M, Mirzaei H, Reza Mirzaei H, Salehi R, Ferns GA, Ghayour-Mobarhan M, Avan A. 2016. The potential for circulating microRNAs in the diagnosis of myocardial infarction: A novel approach to disease diagnosis and treatment. Curr Pharm Des 22:397–403.
41. Gloire G, Legrand-Poels S, Piette J. 2006. NF-κB activation by reactive oxygen species: Fifteen years later. Biochem Pharmacol 72:1493–1505.
42. Gremmels H, Bevers LM, Fledderus JO, Braam B, van Zonneveld AJ, Verhaar MC, Joles JA. 2015. Oleic acid increases mitochondrial reactive oxygen species production and decreases endothelial nitric oxide synthase activity in cultured endothelial cells. Eur J Pharmacol 751:67–72.
43. Griendling KK, Sorescu D, Ushio-Fukai M. 2000. NAD (P) H oxidase role in cardiovascular biology and disease. Circ Res 86:494–501.
44. Hecker M, Sessa WC, Harris HJ, Anggård E, Vane JR. 1990. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: Cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 87:8612–8616.
45. Hemmens B, Goessler W, Schmidt K, Mayer B. 2000. Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase. J Biol Chem 275:35786–35791.
46. Hoff HF, Zyromski N, Armstrong D, O'Neil J. 1993. Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages. J Lipid Res 34:1919–1929.
47. Holvoet P, De Keyzer D, Jacobs DR, Jr. 2008. Oxidized LDL and the metabolic syndrome.
48. Honarbakhsh S, Schachter M. 2009. Vitamins and cardiovascular disease. Br J Nutr 101:1113–1131.
49. Hooper P, Hooper J. 2004. Vitamin E and atherosclerosis. Prev Cardiol 7:144.
50. Hopkins PN. 2013. Molecular biology of atherosclerosis. Physiol Rev 93:1317–1542.
51. Hosin AA, Prasad A, Viiri LE, Davies AH, Shalhoub J. 2014. MicroRNAs in atherosclerosis. J Vasc Res 51:338–349.
52. Itabe H. 2009. Oxidative modification of LDL: Its pathological role in atherosclerosis. Clin Rev Allergy Immunol 37:4–11.
53. Janjetovic Z, Zmijewski MA, Tuckey RC, DeLeon DA, Nguyen MN, Pfeffer LM, Slominski AT. 2009. 20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-κB activity by increasing IκBα levels in human keratinocytes. PLoS ONE 4:5988.
54. Jiang Q, Ames BN. 2003. γ-Tocopherol, but not α-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 17:816–822.
55. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. 2000. γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 97:11494–11499.
56. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. 2007. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 58:191.
57. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. 2013. Role of vitamin D in atherosclerosis. Circulation 128:2517–2531.
58. Kawashima S, Yokoyama M. 2004. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Thromb Vasc Biol 24:998–1005.
59. Khor T. 2000. Effects of administration of α-tocopherol and tocotrienols on serum lipids and liver HMG CoA reductase activity. Int J Food Sci Nutr 51:S11.
60. Kim JG, Taylor WR, Parthasarathy S. 1999. Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxide-modified anti-peptide antibody. Atherosclerosis 143:335–340.
61. Kinlay S, Libby P, Ganz P. 2001. Endothelial function and coronary artery disease. Curr Opin Lipidol 12:383–389.
62. Kockx MM. 1998. Apoptosis in the atherosclerotic plaque quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 18:1519–1522.
63. Kockx MM, De Meyer GR, Muhring J, Bult H, Bultinck J, Herman AG. 1996. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis 120:115–124.
64. Kruth HS, Huang W, Ishii I, Zhang W-Y. 2002. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 277:34573–34580.
65. Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ. 2000. Coronary microvascular endothelial cell redox state in left ventricular hypertrophy the role of angiotensin II. Circ Res 86:463–469.
66. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. 2001. Endothelial regulation of vasomotion in apoE-deficient mice implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103:1282–1288.
67. Lavie CJ, Lee JH, Milani RV. 2011. Vitamin Milani and cardiovascular disease: Will it live up to its hype? J Am Coll Cardiol 58:1547–1556.
68. Lee SJ, Choi EK, Seo KW, Bae JU, Kim YH, Park SY, Oh SO, Kim CD. 2013. 5-Lipoxygenase plays a pivotal role in endothelial adhesion of monocytes via an increased expression of Mac-1. Cardiovasc Res 99:724–733.
69. Li J-M, Shah AM. 2003. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II ROLE OF THE p47 phox SUBUNIT. J Biol Chem 278:12094–12100.
70. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA, Sessa WC. 2003. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 278:44719–44726.
71. Lüscher TF, Barton M. 1997. Biology of the endothelium. Clin Cardiol 20:II-3–II-10.
72. Maas R. 2005. On asymmetric dimethylargine (ADMA). Vasc Med 10:S49–S57.
73. Mabile L, Bruckdorfer KR, Rice-Evans C. 1999. Moderate supplementation with natural α-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation. Atherosclerosis 147:177–185.
74. Madrigal-Matute J, Rotllan N, Aranda JF, Fernández-Hernando C. 2013. MicroRNAs and atherosclerosis. Curr Atheroscler Rep 15:1–8.
75. McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP, Group PDoAiYR. 2000. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 72:1307s–1315s.
76. McIntyre BS, Briski KP, Gapor A, Sylvester PW. 2000. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224:292–301.
77. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA. 2000. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA 97:1506–1511.
78. Menezes AR, Lamb MC, Lavie CJ, DiNicolantonio JJ. 2014. Vitamin d and atherosclerosis. Curr Opin Cardiol 29:571–577.
79. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Hovingh GK, Farnier M. 2015. Analysis of vitamin D levels in patients with and without statin-associated myalgia—A systematic review and meta-analysis of 7 studies with 2420 patients. Int J cardiol 178:111–116.
80. Milenkovic D, Deval C, Gouranton E, Landrier J-F, Scalbert A, Morand C, Mazur A. 2012. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: A new mechanism of the action of polyphenols. PLoS ONE 7:e29837.
81. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. 2005. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37–46.
82. Mirzaei Reza H. 2016. Circulating microRNAs in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers. Curr Pharm Des 22:5257–5269.
83. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jafaari MR, Mirzaei HR, Hassanian SM, Avan A. 2016a. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 53:25–32.
84. Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Reza Mirzaei H, Salehi H, Peyvandi M, Pawelek JM, Sahebkar A. 2016b. Curcumin: A new candidate for melanoma therapy. Int J Cancer.
85. Mirzaei H, Khataminfar S, Mohammadparast S, Shahid Sales S, Maftouh M, Mohammadi M, Simonian M, Mohammd Reza Parizadeh S, Mahdi Hassanian S, Avan A. 2016c. Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives. Curr Med Chem 23:4135–4150.
86. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. 2014. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 20:1126–1167.
87. Mo B, Liu W, Yang L, Jiao J. 2007. Modulation of expression of platelet-derived growth factor by nuclear transcription factor-kappaB in rats retina. Zhonghua yan ke za zhi 43:49–54.
88. Moens AL, Kass DA. 2006. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 26:2439–2444.
89. Mohamadpour AH, Abdolrahmani L, Mirzaei H, Sahebkar A, Moohebati M, Ghorbani M, Ferns GA, Ghayour-Mobarhan M. 2015. Serum osteopontin concentrations in relation to coronary artery disease. Arch Med Res 46:112–117.
90. Mohammadi M, Goodarzi M, Jaafari M, Mirzaei H, Mirzaei H. 2016. Circulating microRNA: A new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther.
91. Molloy K, Thompson M, Jones J, Schwalbe E, Bell P, Naylor A, Loftus I. 2004. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110:337–343.
92. Mugoni V, Postel R, Catanzaro V, De Luca E, Turco E, Digilio G, Silengo L, Murphy MP, Medana C, Stainier DY. 2013. Ubiad1 is an antioxidant enzyme that regulates eNOS activity by CoQ10 synthesis. Cell 152:504–518.
93. Munteanu A, Zingg JM, Azzi A. 2004. Anti-atherosclerotic effects of vitamin E-myth or reality? J Cellular Mol Med 8:59–76.
94. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1–13.
95. Newaz MA, Nawal N, Rohaizan C, Muslim N, Gapor A. 1999. α-Tocopherol increased nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats. Am J Hypertens 12:839–844.
96. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF. 1998. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 97:2494–2498.
97. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB. 2009. 1, 25 (OH) 2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 120:687–698.
98. Pal S, Thomson AM, Bottema CD, Roach PD. 2003. α-Tocopherol modulates the low density lipoprotein receptor of human HepG2 cells. Nutr J 2:1.
99. Palmer RM, Ferrige A, Moncada S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526.
100. Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, Rahsepar AA, Amini M, Sahebkar A, Mohammadi M. 2011. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids 46:333–340.
101. Park YM, Febbraio M, Silverstein RL. 2009. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 119:136–145.
102. Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G, Ceriello A. 2006. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 22:198–203.
103. Pieper GM, Langenstroer P, Siebeneich W. 1997. Diabetic-induced endothelial dysfunction in rat aorta: Role of hydroxyl radicals. Cardiovasc Res 34:145–156.
104. Pober JS, Min W, Bradley JR. 2009. Mechanisms of endothelial dysfunction, injury, and death. Ann Rev Pathol 4:71–95.
105. Radomski MW, Palmer R, Moncada S. 1987. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 92:639–646.
106. Raman C, Li H, Martásek P, Král V, Masters BSS, Poulos TL. 1998. Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pterin function involving a novel metal center. Cell 95:939–950.
107. Rashidi B, Mohammadi M, Mirzaei F, Badalzadeh R, Reisi P. 2011. Amlodipine treatment decreases plasma and carotid artery tissue levels of endothelin-1 in atherosclerotic rabbits. Pathophysiology 18:137–142.
108. Rebsamen MC, Sun J, Norman AW, Liao JK. 2002. 1α, 25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 91:17–24.
109. Ricciarelli R, Maroni P, Özer N, Zingg J-M, Azzi A. 1999. Age-dependent increase of collagenase expression can be reduced by α-tocopherol via protein kinase C inhibition. Free Radic Biol Med 27:729–737.
110. Ricciarelli R, Zingg J-M, Azzi A. 2000. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 102:82–87.
111. Rimbach G, Minihane AM, Majewicz J, Fischer A, Pallauf J, Virgli F, Weinberg PD. 2002. Regulation of cell signalling by vitamin E. Proc Nutr Soc 61:415–425.
112. Rizvi S, Raza ST, Ahmed F, Ahmad A, Abbas S, Mahdi F. 2014. The role of vitamin E in human health and some diseases. Sultan Qaboos Univ Med J 14:157.
113. Saadatpour L, Fadaee E, Fadaei S, Nassiri Mansour R, Mohammadi M, Mousavi SM, Goodarzi M, Verdi J, Mirzaei H. 2016. Glioblastoma: Exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther 23:415–418.
114. Salarini R, Sahebkar A, Mirzaei H, Jaafari M, Riahi M, Hadjati J, Asrami M, Fdaee S, Salehi R, Mirzaei H. 2015. Epi-drugs and Epi-miRs: Moving beyond current cancer therapies. Curr Cancer Drug Targets.
115. Saldeen T, Li D, Mehta JL. 1999. Differential effects of α-and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 34:1208–1215.
116. Salehi E, Khazaei M, Rashidi B. 2011. Role of GW0742 a PPARβ/δ agonist on Coronary angiogenesis in control and diabetic rats. J Isfahan Med School 29.
117. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. 2000. Role of NAD (P) H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87:1195–1201.
118. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. 2008. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. Jama 300:2123–2133.
119. Sheane J, Smyth P, Scott K, Aziz R, Buckley M, Lodge E, Kiely N, Kingston M, McGovern E, Healy M. 2015. An association between microRNA-21 expression and vitamin d deficiency in Coronary artery disease. MicroRNA 4:57–63.
120. Sheppard A, Pennington J, Weihrauch J. 1993. Analysis and distribution of vitamin E in vegetable oils and foods. Vitam E Health Dis 9–31.
121. Shimizu S, Ishii M, Miyasaka Y, Wajima T, Negoro T, Hagiwara T, Kiuchi Y. 2005. Possible involvement of hydroxyl radical on the stimulation of tetrahydrobiopterin synthesis by hydrogen peroxide and peroxynitrite in vascular endothelial cells. Int J Biochem Cell Biol 37:864–875.
122. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R. 1999. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 48:2437–2445.
123. Shklar G, Oh S-K. 2000. Experimental Basis for Cancer Preventation by Vitamin E. Cancer Invest 18:214–222.
124. Simonian M, Mosallayi M, Mirzaei H. 2016. Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker.
125. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. 1993. Vitamin E consumption and the risk of coronary disease in women. N Eng J Med 328:1444–1449.
126. Steingberg D. 1889. Beyond cholesterol modification of low density lipoprotein that increase its atherogenecity. N Eng J 320:915–924.
127. Stocker R. 1999. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol 10:589–598.
128. Stroes E, Hijmering M, Van Zandvoort M, Wever R, Rabelink T, Van Faassen E. 1998. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 438:161–164.
129. Stuehr DJ. 1997. Structure-function aspects in the nitric oxide synthases. Ann Rev Pharmacol Toxicol 37:339–359.
130. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC. 2006. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 291:E315–E322.
131. Sun J, Zhong W, Gu Y, Groome LJ, Wang Y. 2014. 1, 25 (OH) 2 D 3 suppresses COX-2 up-regulation and thromboxane production in placental trophoblast cells in response to hypoxic stimulation. Placenta 35:143–145.
132. Suzuki YJ, Packer L. 1993. Inhibition of NF-κB activation by vitamin E derivatives. Biochem Biophys Res Commun 193:277–283.
133. Tan DT, Khor H, Low W, Ali A, Gapor A. 1991. Effect of a palm-oil-vitamin E concentrate on the serum and lipoprotein lipids in humans. Am J Clin Nutr 53:1027S–1030S.
134. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, Toprak A, Yazici D, Sancak S, Deyneli O. 2009. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 94:4023–4030.
135. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kübler W. 2000. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 102:2172–2179.
136. Upston JM, Kritharides L, Stocker R. 2003. The role of vitamin E in atherosclerosis. Prog Lipid Res 42:405–422.
137. Vásquez-Vivar J, Kalyanaraman B, Martásek P, Hogg N, Masters BSS, Karoui H, Tordo P, Pritchard KA. 1998. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 95:9220–9225.
138. Vásquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. 2002. Altered tetrahydrobiopterin metabolism in atherosclerosis implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 22:1655–1661.
139. Van de Luijtgaarden K, Voute M, Hoeks S, Bakker EJ, Chonchol M, Stolker R, Rouwet E, Verhagen H. 2012. Vitamin D deficiency may be an independent risk factor for arterial disease. Eur J Vasc Endovasc Surg 44:301–306.
140. Wallert M, Schmölz L, Galli F, Birringer M, Lorkowski S. 2014. Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Biol 2:495–503.
141. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. 2008. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–511.
142. Wentland AL, Grist TM, Wieben O. 2014. Review of MRI-based measurements of pulse wave velocity: A biomarker of arterial stiffness. Cardiovasc Diagn Ther 4:193–206.
143. Wilcox CS. 2002. Reactive oxygen species: Roles in blood pressure and kidney function. Curr Hypertens Rep 4:160–166.
144. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. 1995. Transcriptional roles of nuclear factor B and nuclear factor-interleukin-6 in the tumor necrosis factor-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270:31315–31320.
145. Yoshida H, Kisugi R. 2010. Mechanisms of LDL oxidation. Clin Chim Acta 411:1875–1882.
146. Yoshikawa T, Yoshida N, Manabe H, Terasawa Y, Takemura T, Kondo M. 1998. α-tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 7:15–19.
147. Yu T, Robotham JL, Yoon Y. 2006. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 103:2653–2658.
148. Yu T, Sheu S-S, Robotham JL, Yoon Y. 2008. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res 79:341–351.
149. Zapolska-Downar D, Zapolski-Downar A, Markiewski M, Ciechanowicz A, Kaczmarczyk M, Naruszewicz M. 2000. Selective inhibition by α-tocopherol of vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Biochem Biophys Res Commun 274:609–615.
150. Zhang H, Schmeißer A, Garlichs CD, Plötze K, Damme U, Mügge A, Daniel WG. 1999. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells. Cardiovasc Res 44:215–222.
151. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E. 2012. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 188:2127–2135.
152. Zhao H, Hiroi T, Hansen BS, Rade JJ. 2009. Cyclic stretch induces cyclooxygenase-2 gene expression in vascular endothelial cells via activation of nuclear factor kappa-β. Biochem Biophys Res Commun 389:599–601.
153. Zitman-Gal T, Green J, Pasmanik-Chor M, Golan E, Bernheim J, Benchetrit S. 2014. Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment. Cardiovasc Diabetol 13:1.